Table 1.
Patients demographics
| Age, years | Sex | Type of Disease | Visual Acuity OD | Visual Acuity OS | Activity OU | Years since first Visit | Years since last recurrence | Treatment OU |
|---|---|---|---|---|---|---|---|---|
| 81 | M | A | 20/32 | – | Inactive | 8 | 3 | Prednisolon |
| 57 | W | A | 20/400 | 20/60 | Inactive | 2.5 | 2.5 | Methotrexate |
| 47 | W | M | 20/125 | 20/2000 | Inactive | 7 | 7 | Methotrexate |
| 34 | W | P | 20/20 | 20/20 | Inactive | 2.8 | 2.8 | Adalimumab |
| 63 | W | P | 20/25 | – | Inactive | 15.7 | 15.7 | Azathioprine |
| 73 | M | P | 20/200 | 20/100 | Inactive | 9 | 2 | Ciclosporine |
| 34 | W | P | 20/20 | 20/50 | Inactive | 1.4 | 1.4 | Ciclosporine |
| 68 | W | P | 20/25 | 20/25 | Inactive | 3.7 | 3.7 | Ciclosporine |
| 54 | W | P | 20/20 | 20/20000 | Inactive | 6 | 3 | Interferon-α |
| 68 | M | P | 20/20 | 20/40 | Inactive | 5.8 | 5.8 | Interferon-α |
| 62 | M | P | 20/2000 | 20/32 | Inactive | 1.6 | 1.6 | Methotrexate + Prednisolon |
| 79 | W | P | 20/20000 | 20/20 | Inactive | 6 | 6 | – |
A atypical; M macular; P peripapillary; OD right eye; OS left eye; OU both eyes